<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2106233832
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Imla
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PRILOCAINE,LIDOCAINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.50,2.50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        % (W/W)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Topical
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Cream
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tube
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        47.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AJA PHARMACEUTICAL INDUSTRIES" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1916]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Imla Cream contains two active substances called lidocaine and prilocaine. These belong to a group of medicines called local anaesthetics.</p><p>Imla Cream works by numbing the surface of the skin for a short time. It is put on the skin before certain medical procedures. This helps to stop pain on the skin; however you may still have the feelings of pressure and touch.</p><p>Adults, Adolescents and Children It can be used to numb the skin before:</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Having a needle put in (for example, if you are having an injection or a blood test).</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Minor skin operations.</p><p>Adults and Adolescents</p><p>It can also be used:</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To numb the genitals before:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Having an injection.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medical procedures such as removal of warts.</p><p>A doctor or nurse should apply Imla Cream on the genitals.</p><p>Adults</p><p>It can also be used to numb the skin before:</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cleansing or removal of damaged skin of leg ulcers.</p><p>For other purposes than application to intact skin, the product should be used only upon recommendation of a doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do</strong><strong> </strong><strong>not</strong><strong> </strong><strong>use</strong><strong> </strong><strong>Imla</strong><strong> Cream:</strong></p><p>a.&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to lidocaine or prilocaine, other similar local anaesthetics or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>Warnings</strong><strong> and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using Imla Cream:</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; if you or your child have a rare inherited illness that affects the blood called &lsquo;glucose-6-phosphate dehydrogenase deficiency&rsquo;.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp; if you or your child have a problem with blood pigment levels called &lsquo;methaemoglobinaemia&rsquo;.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp; Do not use Imla Cream on areas with skin rash, cuts, grazes or other open wounds, with the exception of a leg ulcer. If any of these problems are present, check with your doctor, pharmacist or nurse before using the cream.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp; if you or your child have an itchy skin condition called &lsquo;atopic dermatitis&rsquo;, a shorter application time may be sufficient.</p><p>Application times of longer than 30 minutes may result in an increased incidence of local skin reaction (see also section 4 &ldquo;Possible side effects&rdquo;).</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you take particular products for heart rhythm disorders (class III antiarrhythmics, such as amiodarone). In that case the doctor will monitor your heart function.</p><p>Due to the potentially enhanced absorption on the newly shaven skin, it is important to follow the recommended dosage, skin area and application time.</p><p>Avoid getting Imla Cream in the eyes, as it may cause irritation. If you accidentally get Imla Cream in your eye, you should immediately rinse</p><p>it well with lukewarm water or salt (sodium chloride) solution. Be careful to avoid getting anything in your eye until feeling returns.</p><p>Imla Cream should not be applied to an impaired eardrum.</p><p>When you use Imla Cream before being vaccinated with live vaccines (e.g. tuberculosis vaccine), you should return to your doctor or pharmacist after the time period requested to follow-up the vaccination result.</p><p><strong>Children and adolescents</strong><strong> </strong>In infants/newborn infants younger than 3 months a transient, clinically not relevant increase in blood pigment levels &ldquo;methaemoglobinaemia&rdquo; is commonly observed up to 12 hours after Imla Cream is put on.</p><p>The effectiveness of Imla Cream when drawing blood from the heel of newborn infants or to provide adequate analgesia for circumcision could not be confirmed in clinical studies.</p><p>Imla Cream should not be applied to the genital skin (e.g. penis) and genital mucosa (e.g. in the vagina) of children (below 12 years of age) owing to insufficient data on absorption of active substances.</p><p>Imla Cream should not be used in children younger than 12 months of age who are being treated at the same time with other medicines that affect blood pigment levels &ldquo;methaemoglobinaemia&rdquo; (e.g.</p><p>sulphonamides, see also Section 2 Other medicines and Imla Cream).</p><p>Imla Cream should not be used in preterm newborn infants.</p><p>Other medicines and Imla Cream Tell your doctor or pharmacist if you are using / taking, have recentlyused / taken or might use / take</p><p>any other medicines. This includes medicines that you buy without a prescription and herbal medicines. This is because Imla Cream can affect the way some medicines work and some medicines can have an effect on Imla Cream.</p><p>In particular, tell your doctor or pharmacist if you or your child have recently used or been given any of the following medicines:</p><p>&bull;&nbsp; Medicines used to treat infections, called &lsquo;sulphonamides&rsquo; and nitrofurantoin.</p><p>&bull;&nbsp; Medicines used to treat epilepsy, called phenytoin and phenobarbital.</p><p>&bull;&nbsp; Other local anaesthetics.</p><p>&bull;&nbsp; Medicines to treat an uneven heartbeat, such as amiodarone.</p><p>&bull;&nbsp; Cimetidine or beta-blockers, which may cause an increase in the blood levels of lidocaine.</p><p>This interaction is of no clinical relevance in short-term treatment with Imla Cream in recommended doses.</p><p>Pregnancy, breastfeeding and fertility</p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>Occasional use of Imla Cream during pregnancy is unlikely to have any adverse effects on the foetus.</p><p>The active substances in Imla Cream (lidocaine and prilocaine) are passed into breast milk. However, the amount is so small that there is generally no risk to the child.</p><p>Animal studies have shown no impairment of male or female fertility.</p><p>Driving and using machines:</p><p>Imla Cream has no or negligible influence on the ability to drive and use machines when used at the recommended doses.</p><p>Imla Cream contains macrogolglycerol hydroxystearate which may cause skin reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use Imla Cream exactly as described in this leaflet or as your doctor or pharmacist has told you.</p><p>Check with your doctor, pharmacist or nurse if you are not sure.</p><p>This product is available in different pack sizes. You will have been provided with a suitable pack size for your intended use.</p><p>Using Imla Cream</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp; Where to put the cream, how much to use and how long to leave it on will depend on what it is used for.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Imla Cream should be used on the genitals only by a doctor or nurse.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp; When Imla Cream is used on leg ulcers, a doctor or nurse should supervise its use.</p><p>Do not use Imla Cream on the following areas:</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp; Cuts, grazes or wounds, excluding leg ulcers.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp; Where there is a skin rash or eczema.</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In or near the eyes.</p><p>g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inside the nose, ear or mouth.</p><p>h.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the back passage (anus).</p><p>i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On the genitals of children.</p><p>Persons frequently applying cream should ensure that contact is avoided in order to prevent the development of hypersensitivity.</p><p>The protective membrane of the tube is perforated by applying the cap.</p><p>Use on the skin before small procedures (such as having a needle put in or minor skin operations):</p><p>j.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The cream is put on to the skin in a thick layer. Follow the instructions on the leaflet or those from your health care</p><p>professional. In certain cases your healthcare professional has to apply the cream.</p><p>k.&nbsp;&nbsp;&nbsp;&nbsp; The cream is then covered by a dressing [plastic wrap]. This is taken off just before the procedure starts. If you are applying the cream yourself, make sure that you have been</p><p>given dressings by your doctor, pharmacist or nurse.</p><p>l.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose for adults and adolescents over 12 years is 2 g (grams).</p><p>m.&nbsp;&nbsp; For adults and adolescents over 12 years put the cream on at least 60 minutes before the procedure (unless the cream is being used on the genitals). However, do not put it on more than 5 hours before.</p><p>Children</p><p>Use on the skin before small procedures (such as having a needle put in or minor skin operations) Application time: approx. 1 hour.</p><p>Newborn infants and infants 0-2 months: Up to 1 g of cream on a skin area not larger than 10 cm2 (10 square centimetres) in size.</p><p>&nbsp;</p><p>Application time: 1hour, not more. Only one single dose should be given in any 24 hour period.</p><p>Infants aged 3-11 months: Up to 2 g of cream on a total skin area not larger than 20 cm2 (20 square centimetres) in size. Application time: approx 1 hour.</p><p>Children aged 1-5 years: Up to 10 g of cream on a total skin area not larger than 100 cm2 (100 square centimetres) in size. Application time: approx 1 hour, maximum 5 hours.</p><p>Children aged 6-11 years: Up to 20 g of cream on a total skin area not larger than 200 cm2 (200 square centimetres) in size. Application time: approx 1 hour, maximum 5 hours.</p><p>A maximum of 2 doses at least 12 hours apart may be given to children over 3 months of age in any 24 hour period.</p><p>Imla Cream can be used on children with a skin condition called &ldquo;atopic dermatitis&rdquo; but the application time is then 30 minutes, no longer.</p><p>Use on larger areas of newly shaven skin before outpatient procedures (such as hair removal techniques):</p><p>Follow the instructions from your healthcare professional.</p><p>The usual dose is 1 g of cream for each area of skin that is 10 cm&sup2; (10 square centimetres) in size, applied for 1 to 5 hours under a sterile dressing. Imla Cream should not be used on an area of newly shaven skin larger than 600 cm&sup2; (600 square centimetres, e.g. 30 cm by 20 cm) in size. The maximum dose is 60 g.</p><p>Use on the skin before hospital procedures (such as split-skin grafting) that require deeper skin anaesthesia:</p><p>&bull;&nbsp; Imla Cream can be used in this way on adults and adolescents over 12 years, but only under the supervision of a doctor or nurse.</p><p>&bull;&nbsp; The usual dose is 1.5 g to 2 g of cream for each area of skin that is 10 cm&sup2; (10 square centimetres) in size.</p><p>&bull;&nbsp; The cream is put on on under a sterile dressing for 2 to 5 hours.</p><p>Use on the skin prior to removal of wart-like spots called &ldquo;mollusca&rdquo;</p><p>&bull;&nbsp; Imla Cream can be used on children and adolescents with a skin condition called &ldquo;atopic dermatitis&rdquo;.</p><p>&bull;&nbsp; The usual dose depends on the child&rsquo;s age and is used for 30 to 60 minutes (30 minutes if the patient has atopic dermatitis). Your doctor, nurse or pharmacist will tell you how much cream to use.</p><p>Use on genital skin before injections of local anaesthetics</p><p>&bull;&nbsp; Imla Cream can be used in this way only by healthcare professionals on adults and adolescents over 12 years.</p><p>&bull;&nbsp; The usual dose is 1 g of cream (1 g to 2 g for female genital skin) for each area of skin that is 10 cm&sup2; (10 square centimetres) in size.</p><p>&bull;&nbsp; The cream is put on under a sterile dressing. This is done for 15 minutes on male genital skin and for 60 minutes on female genital skin.</p><p>Use on the genitals before minor skin surgery (such as removal of warts)</p><p>&bull;&nbsp; Imla Cream can be used in this way only by healthcare professionals on adults and adolescents over 12 years.</p><p>&bull;&nbsp; The usual dose is 5 g to 10 g of cream for 10 minutes. A</p><p>dressing is not used. The medical procedure should then start straight away.</p><p>Use on leg ulcers before cleaning or removal of damaged skin</p><p>&bull;&nbsp; Imla Cream can be used in this way in adults, but only under the supervision of a doctor or nurse.</p><p>&bull;&nbsp; The usual dose is 1 g to 2 g of cream for each area of skin that is 10 cm2 up to a total of 10 g.</p><p>&bull;&nbsp; The cream is put on under an airtight dressing such as plastic wrap. This is done for 30 to 60 minutes before the ulcer is to be cleansed. Remove the cream with cotton gauze and start cleansing without delay.</p><p>&bull;&nbsp; Imla Cream can be used before cleansing of leg ulcers for up to 15 times over a period of 1 - 2 months.</p><p>&bull;&nbsp; The Imla Cream tube is intended for single use when used on</p><p>leg ulcers: The tube with any remaining contents should be discarded after each occasion that a patient has been treated.</p><p>If you use more Imla Cream than you should</p><p>If you use more Imla Cream than is described in this leaflet or more than your doctor or pharmacist has told you to, talk to one of them straight away, even if you do not feel any symptoms.</p><p>Symptoms of using too much Imla Cream are listed below. These symptoms are unlikely to happen if Imla Cream is used as recommended.</p><p>&bull;&nbsp; Feeling light-headed or dizzy.</p><p>&bull;&nbsp; Tingling of the skin around the mouth and numbness of the tongue.</p><p>&bull;&nbsp; Abnormal taste.</p><p>&bull;&nbsp; Blurred vision.</p><p>&bull;&nbsp; Ringing in the ears.</p><p>&bull;&nbsp; There is also a risk of &lsquo;acute methaemoglobinaemia&rsquo; (a problem with blood pigment</p><p>blood pressure, slowed breathing, stopped breathing and altered heartbeat. These effects may be life-threatening.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Contact your doctor or pharmacist if any of the following side effects bother you or do not seem to</p><p>go away. Tell your doctor about anything else that makes you feel unwell while you are using Imla Cream.</p><p>If you experience any of the following effects while you are using Imla Cream, stop using it and check with your doctor or pharmacist as soon as possible:</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions, which in rare cases may develop into anaphylactic shock (skin rash, swelling, fever, respiratory difficulties and fainting) during</p><p>treatment of skin, genital mucosa or leg ulcers.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Methaemoglobinaemia (blood disorder), which in rare cases may develop during treatment of the skin, and may cause signs and symptoms of hypoxaemia (abnormally low level of oxygen in the blood).</p><p>Methaemoglobinaemia is more frequently observed, often in connection with overdose, in newborn infants and infants aged 0 to 12 months.</p><p>A mild reaction (paleness or redness of the skin, slight puffiness, initial burning or itching) may occur on the area on which Imla is used.</p><p>These are normal reactions to the cream and the anaesthetics and will disappear in a short while without any measures being needed.</p><p>If you experience any troublesome or unusual effects while you are using Imla, stop using it and check with your doctor or pharmacist as soon as possible.</p><p>Common (may affect up to 1 in 10 people)</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp; Transient local skin reactions (paleness, redness, swelling) in the treated area during treatment of skin, genital mucosa or leg ulcers.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp; An initially mild sensation of burning, itching or warmth at the treated area during treatment of genital mucosa or leg ulcers.</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp; An initially mild sensation of burning, itching or warmth at the treated area during treatment of the skin).</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness (tingling) in the treated area during treatment of genital mucosa.</p><p>g.&nbsp;&nbsp;&nbsp;&nbsp; Irritation of the treated skin during treatment of leg ulcers.</p><p>Rare (may affect up to 1 in 1,000 people)</p><p>h.&nbsp;&nbsp;&nbsp;&nbsp; Small dot-shaped bleeding on the treated area (particularly on children with eczema after</p><p>longer application times) during treatment of the skin.</p><p>i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritation of the eyes if Imla Cream accidentally comes into contact with them during treatment of the skin.</p><p>Reporting of side effects</p><p>j.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Textbox_x0020_27" o:spid="_x0000_s1026" type="#_x0000_t202"
 style='width:211.75pt;height:95.5pt;visibility:visible;mso-wrap-style:square;
 mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokecolor="#231f20" strokeweight=".25pt">
 <v:path arrowok="t"/>
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:4.6pt;margin-right:6.55pt;margin-bottom:
    0in;margin-left:4.1pt;margin-bottom:.0001pt;text-indent:-2.85pt;mso-list:
    l1 level1 lfo2;tab-stops:4.1pt'><![if !supportLists]><span
    style='font-size:5.0pt;color:#231F20;mso-font-width:51%'><span
    style='mso-list:Ignore'>•<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
    dir=LTR></span><span style='font-size:12.0pt;font-family:"Times New Roman",serif;
    mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
    major-bidi;color:#231F20'>The National Pharmacovigilance Centre (NPC)<o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:2.25pt;margin-right:0in;margin-bottom:
    0in;margin-left:6.9pt;margin-bottom:.0001pt;text-indent:-2.8pt;mso-list:
    l1 level2 lfo2;tab-stops:6.9pt'><![if !supportLists]><span
    style='font-size:5.0pt;color:#231F20;mso-font-width:51%'><span
    style='mso-list:Ignore'>•<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='font-size:12.0pt;font-family:"Times New Roman",serif;
    mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
    major-bidi;color:#231F20'>Phone number: 19999<o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:2.25pt;margin-right:0in;margin-bottom:
    0in;margin-left:6.9pt;margin-bottom:.0001pt;text-indent:-2.8pt;mso-list:
    l1 level2 lfo2;tab-stops:6.9pt'><![if !supportLists]><span
    style='font-size:5.0pt;color:#231F20;mso-font-width:51%'><span
    style='mso-list:Ignore'>•<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='font-size:12.0pt;font-family:"Times New Roman",serif;
    mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
    major-bidi;color:#231F20'>E-mail: </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='font-size:12.0pt;
    font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
    mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:#231F20;
    text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><span
    style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
    major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
    color:#231F20'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:2.25pt;margin-right:0in;margin-bottom:
    0in;margin-left:6.9pt;margin-bottom:.0001pt;text-indent:-2.8pt;mso-list:
    l1 level2 lfo2;tab-stops:6.9pt'><![if !supportLists]><span
    style='font-size:5.0pt;color:#231F20;mso-font-width:51%'><span
    style='mso-list:Ignore'>•<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='font-size:12.0pt;font-family:"Times New Roman",serif;
    mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
    major-bidi;color:#231F20'>Website: </span><a
    href="http://www.sfda.gov.sa/npc"><span style='font-size:12.0pt;font-family:
    "Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
    major-bidi;mso-bidi-theme-font:major-bidi;color:#231F20;text-decoration:
    none;text-underline:none'>www.sfda.gov.sa/npc</span></a><span
    style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
    major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
    color:#231F20'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="286" height="131" alt="Text Box: •	The National Pharmacovigilance Centre (NPC)
•	Phone number: 19999
•	E-mail: npc.drug@sfda.gov.sa
•	Website: www.sfda.gov.sa/npc
" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:211.75pt;height:95.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>k.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC Slates:</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C, Do not freeze</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each gm of Imla contains 25 mg of Lidocaine and 25 mg of Prilocaine in a white cream base.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Imla cream is an Oil/Water emulsion in which the oil phase consist of an eutectic mixture of Lidocaine and Prilocaine in the ratio 1:1.
In addition to the active ingredients; It is contain: Macrogolglycerol hydroxystearate, Carbomer 974P, sodium hydroxide, purified water.
Imla cream is available in a pack contains 25 gm aluminium tube.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder&nbsp;<br />AJA Pharmaceutical Industries Company, Ltd.Hail Industrial City MODON,<br />Street No 32<br />PO Box 6979 , Hail 55414<br />Kingdom of Saudi Arabia<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 12/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><p>يعمل كريم ايملا 5% عن طريق تخدير سطح الجلد لفترة قصيرة. يتم وضعه على الجلد قبل إجراءات طبية معينة. يساعد على وقف الألم على الجلد. ومع ذلك قد تشعر بالضغط واللمس.</p><p>&nbsp;</p><p>&nbsp;</p><p>الكبار والمراهقون والأطفال</p><p>يمكن استخدامه لتخدير الجلد قبل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ادخال ابرة (على سبيل المثال، اذا كنت ستحصل على حقنة أو فحص دم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عمليات الجلد البسيطة</p><p>&nbsp;</p><p>الكبار والمراهقون</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويمكن استخدامه أيضا:</p><p>لتخدير الأعضاء التناسلية قبل:</p><p dir="RTL">v&nbsp;&nbsp;&nbsp; أخذ حقنة.</p><p dir="RTL">v&nbsp;&nbsp;&nbsp; الإجراءات الطبية مثل إزالة الثآليل.</p><p dir="RTL">يجب على الطبيب أو الممرض تطبيق كريم ايملا %5 على الأعضاء التناسلية.</p><p>&nbsp;</p><p>&nbsp;</p><p>الكبار</p><p>يمكن استخدامه أيضا لتخدير لجلد قبل:</p><p dir="RTL">تطهير أو إزالة الجلد التالف من تقرحات الساق.</p><p>لأغراض أخرى غير وضعه على الجلد.</p><p>يجب استخدام المنتج فقط بناء على توصية الطبيب والصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستعمل هذا الدواء:</p><p dir="RTL">إذا كانت لديك حساسية للمواد الفعالة, أو إلى أي من المركبات الإضافية التي يحتويها الدواء, أو إلى مُخدّر موضعي آخر مماثل.</p><p dir="RTL">(مذكورة في القسم رقم 6)</p><table cellspacing="0" cellpadding="0" align="right"><tbody><tr><td style="vertical-align:top"><p dir="RTL">تحذيرات خاصة بشأن استعمال الدواء:</p><p dir="RTL">قبل العلاج بكريم إيملا 5% أخبر الطبيب إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك أو لدى طفلك مرض وراثي نادر يؤثر على الدم, الذي يسمى &quot;نقص اﻟجلوكوز- 6-فوسفات دي هيدروجيناز&quot;حساسية الفول (GDPD) انزيم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك أو لدى طفلك مشكلة في مستويات الصباغ في الدم التي تسمى &quot;ميتهيموغلوبينيَّة الدَّم&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجوز استعمال كريم إيملا % 5 في المناطق التي يوجد بها طفح جلدي, شقوق, جَلف, خدوش أو جروح مفتوحة أخرى، باستثناء القرحة في الساق. إذا كان أيّ من هذه المشاكل موجودة, تحقّق مع الطبيب أو الصيدلي قبل استعمال الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني أنت أو طفلك من حالة تهيّج في الجلد التي تُسمى &quot;الْتِهاب الجِلد التّأَتّبِي&quot;. يحتمل بأن مدة مكوث أقصر على الجلد ستكون كافية. إبقاء الكريم على الجلد لمدة تزيد عن 30 دقيقة يمكن أن تسبب ارتفاعًا بردود فعل جلدية موضعية )أنظر أيضًا بند 4 &quot;الأعراض الجانبية&quot;(.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول أدوية معينة لاضطرابات بنظم القلب (مثل أميدارون) في هذه الحالة سيقوم الطبيب برصد وظيفة القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد إمكانية الامتصاص المتزايد في الجلد المحلوق حديثًا, من المهم اتباع الجرعة الموصى بها, مناطق الجلد ومدة إبقاء الكريم المدهون على سطح الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تجنب دخول كريم إيملا 5% الى داخل العينين, وذلك لان هذا يمكن أن يسببّ تهيجًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا دخل كريم إيملا 5% عن طريق الخطأ الى العينين, يجب شطف العينين على الفور جيدًا بماء فاتر أو بمحلول مياه مالحة (كلوريد الصوديوم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كن حذراً لتجنب دخول أي شيء في العين حتى يعود الإحساس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجوز دهن كريم إيملا % 5 على طبلة أذن متضرّرة.</p></td></tr></tbody></table><p dir="RTL">عند استعمال كريم إيملا % 5 قبل أن يتم تطعيمك بلقاحات حيّة مثل لقاح السّل, يجب عليك العودة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلى الطبيب أو الممرضة بعد الفترة الزمنية المطلوبة لضرورة متابعة نتائج اللقاح.</p><p>&nbsp;</p><p>في الأطفال والمراهقين</p><p>عند الرضع / الأطفال الذين تقل أعمارهم عن 3 أشهر، لوحظ بشكل واضح زيادة عابرة وغير ذات صلة سريريا في مستويات صبغة الدم &quot;ميثيموغلوبين الدم&quot; حتى 12 ساعة بعد وضع كريم ايملا.</p><p>لم يتم تأكيد فعالية كريم ايملا في الدراسات السريرية عند سحب الدم من كعب الأطفال حديثي الولادة أو لتوفير تسكين ألم مناسب للختان.</p><p>لا ينبغي تطبيق كريم ايملا على الجلد التناسلي (مثل القضيب) والغشاء المخاطي للأعضاء التناسلية (على سبيل المثال في المهبل) للأطفال (أقل من 12 عاما) بسبب عدم وجود بيانات كافية حول امتصاص المواد الفعالة.</p><p>لا ينبغي استخدام كريم ايملا في الأطفال الذين تقل أعمارهم عن 12 شهر والذين تقل أعمارهم عن 12 شهر والذين يتم علاجهم في نفس الوقت بادوية أخرى تؤثر على مستويات صبغة الدم &quot;ميثيموغلوبين الدم&quot; (على سبيل المثل السلفوناميدات، انظر أيضا القسم 2: الأدوية الأخرى وكريم ايملا).</p><p>لاينبغي استخدام كريم ايملا عند الأطفال حديثي الولادة.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">التداخلات/التفاعلات بين الأدوية</p><p dir="RTL">إذا كنت تتناول أدوية أخرى مؤخرًا, بما في ذلك الأدوية التي تُصرف دون وصفة طبية والإضافات الغذائية وأدوية نباتية, أخبر الطبيب أو الصيدلي بذلك. وذلك لأن كريم إيملا % 5 يمكن أن يؤثر على كيفية عمل أدوية معينة وبعض الأدوية يمكن أن تؤثر على كريم إيملا 5%</p><p dir="RTL">أخبر طبيبك أو الصيدلي خاصة إذا كنت تأخذ:</p><p dir="RTL">أدوية تستعمل لعلاج الالتهابات, تسمى &quot;سُلفوناميد&quot; ونيتروفورانتوئين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تستعمل لعلاج الصرع, التي تسمى فنيتوئين وفينوباربيتال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُخدّرات موضعيّة أخرى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج عدم انتظام ضربات القلب, مثل أميودارون.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيميتيدين أو حاصرات بيتا, والتي قد تسبب ارتفاعًا في مستويات الليدوكائين في الدم. التفاعل الدوائي هذا ليس بذو أهمية سريريّة في العلاج على المدى القصير مع كريم إيملا 5% في الجرعات الموصى بها.</p><p>&nbsp;</p><p dir="RTL">الحمل, الرضاعة والخصوبة</p><p dir="RTL">إذا كنت حامل أو مرضعة, تعتقدين بأنك حامل أو تخططين للحمل, استشيري الطبيب أو الصيدليّ قبل استعمال هذا الدواء.</p><p dir="RTL">من غير المرجح أن يسبب الاستعمال العرضي لكريم إيملا 5% أثناء الحمل أي أعراض جانبية على الجنين.</p><p dir="RTL">تُفرز المواد الفعالة في كريم إيملا 5% (ليدوكائين وبريلوكائين) في حليب الأم. غير أن, الكمية ضئيلة جداً حيث إنه لا يوجد عموماً خطر على الطفل.</p><p dir="RTL">لم تظهر التجارب على الحيوانات أي ضرّر على خصوبة الذكور أو الإناث.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">القيادة واستعمال الآلات</p><p>كريم إيملا 5% ليس له أي تأثير على الإطلاق أو له تأثير ضئيل على قدرة القيادة واستعمال الآلات عند الاستعمال بالجرعات الموصى بها</p><p>&nbsp;</p><p>ماكروچول غليسيرول هيدروكسيستيرات (macrogolglycerol hydroxystearate) كريم إيملا 5% يحتوي على الذي قد يسبب ردود فعل جلدية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>استخدم كريم ايملا دائما تماما كما هو موصوف في هذه النشرة أو كما اخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي اذا لم تكن متأكدا.</p><p><strong>استخدام كريم ايملا</strong></p><p>مكان وضع الكريم، ومقدار استخدامه ومدة تركه يعتمد على الغرض الذي يستخدم من أجله.</p><p>يجب استخدام كريم ايملا على الأعضاء التناسلية فقط من قبل الطبيب او الممرضة.</p><p>عند استخدام كريم ايملا على تقرحات الساق، يجب على الطبيب أو الممرضة الاشراف على استخدامه</p><p>&nbsp;</p><p>لا تستعمل كريم ايملا في المناطق التالية:</p><p>الجروح أو القروح باستثناء قرح الساق.</p><p>حيث يوجد طفح جلدي أو اكزيما</p><p>في او بالقرب من العينين</p><p>داخل الانف او الاذن او الفم</p><p>في فتحة الشرج</p><p>على الأعضاء التناسلية للأطفال</p><p>يجب على الأشخاص الذين يستخدمون الكريم بشكل متكرر التأكد من تجنب الاتصال لمنع تطور فرط الحساسية.</p><p>يتم ثقب الغشاء الواقي للانبوب عن طريق وضع الغطاء.</p><p>&nbsp;</p><p dir="RTL">ا<strong>ستخدامه على الجلد قبل الإجراءات الصغيرة (مثل إدخال إبرة أو إجراء عمليات جراحية بسيطة في الجلد):</strong></p><p dir="RTL">&bull; يوضع الكريم على الجلد بطبقة سميكة. اتبع التعليمات الموجودة في النشرة أو تلك الخاصة بأخصائي الرعاية الصحية الخاص بك. في بعض الحالات ، يجب على أخصائي الرعاية الصحية الخاص بك وضع الكريم.</p><p dir="RTL">&bull; يُغطى الكريم بعد ذلك بضمادة [غلاف بلاستيكي]. يتم نزع هذا قبل بدء الإجراء مباشرة. إذا كنت تقوم بوضع الكريم بنفسك ، فتأكد من حصولك على الضمادات من قبل طبيبك أو الصيدلي أو الممرض.</p><p dir="RTL">&bull; الجرعة المعتادة للبالغين والمراهقين فوق 12 سنة هي 2 جرام.</p><p dir="RTL">&bull; بالنسبة للبالغين والمراهقين الذين تزيد أعمارهم عن 12 عامًا ، ضع الكريم قبل 60 دقيقة على الأقل من الإجراء (ما لم يتم استخدام الكريم على الأعضاء التناسلية). ومع ذلك ، لا تضعه قبل أكثر من 5 ساعات.</p><table cellspacing="0" cellpadding="0" align="right"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">استخدامه على الجلد قبل الإجراءات الصغيرة (مثل إدخال إبرة أو عمليات الجلد البسيطة) وقت التطبيق: تقريبًا. 1 ساعة.</p><p dir="RTL">الأطفال حديثو الولادة والرضع 0-2 أشهر: ما يصل إلى 1 جرام من الكريم على منطقة لا تزيد عن 10 سم 2 (10 سم مربع). وقت التطبيق: ساعة واحدة وليس أكثر. يجب إعطاء جرعة واحدة فقط في أي فترة 24 ساعة.</p><p dir="RTL">الرضع الذين تتراوح أعمارهم بين 3-11 شهرًا: ما يصل إلى 2 جرام من الكريم على مساحة كلية لا تزيد عن 20 سم 2 (20 سم مربع). وقت التطبيق: حوالي 1 ساعة.</p><p dir="RTL">الأطفال الذين تتراوح أعمارهم بين 1-5 سنوات: ما يصل إلى 10 جم من الكريم على مساحة إجمالية من الجلد لا تزيد عن 100 سم 2 (100 سم مربع) في الحجم. وقت التطبيق: حوالي ساعة واحدة ، بحد أقصى 5 ساعات.</p><p dir="RTL">الأطفال الذين تتراوح أعمارهم بين 6-11 سنة: ما يصل إلى 20 جرامًا من الكريم على مساحة كلية لا تزيد عن 200 سم 2 (200 سم مربع). وقت التطبيق: حوالي ساعة واحدة ، بحد أقصى 5 ساعات.</p><p dir="RTL">يمكن إعطاء جرعتين كحد أقصى بفاصل 12 ساعة على الأقل للأطفال الذين تزيد أعمارهم عن 3 أشهر في أي فترة 24 ساعة.</p><p dir="RTL">يمكن استخدام كريم إيملا على الأطفال الذين يعانون من حالة جلدية تسمى &quot;التهاب الجلد التأتبي&quot; ولكن وقت التطبيق بعد ذلك هو 30 دقيقة ، ليس أكثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدمه في مناطق أكبر من الجلد المحلوق حديثًا قبل إجراءات العيادات الخارجية (مثل تقنيات إزالة الشعر):</strong></p><p dir="RTL">اتبع التعليمات من أخصائي الرعاية الصحية الخاص بك.</p></td></tr></tbody></table><p dir="RTL">الجرعة المعتادة هي 1 جرام من الكريم لكل منطقة من الجلد بحجم 10 سم 2 (10 سم مربع) ، ويتم وضعها لمدة</p><p>1 إلى 5 ساعات تحت ضمادة معقمة. لا ينبغي استخدام كريم إيملا على منطقة من الجلد المحلوق حديثًا أكبر من</p><p dir="RTL">600 سم 2 (600 سم مربع ، على سبيل المثال 30 سم &times; 20 سم). الجرعة القصوى 60 جرام.</p><p dir="RTL"><strong>استخدمه على الجلد قبل إجراءات المستشفى (مثل ترقيع الجلد المشقوق) التي تتطلب تخديرًا أعمق للجلد:</strong></p><p dir="RTL">&bull; يمكن استخدام كريم إيملا بهذه الطريقة على البالغين والمراهقين فوق سن 12 عامًا ، ولكن فقط تحت إشراف طبيب أو ممرض.</p><p dir="RTL">&bull; الجرعة المعتادة هي 1.5 جرام إلى 2 جرام من الكريم لكل منطقة حجمها 10 سم 2 (10 سم مربع).</p><p dir="RTL">&bull; يوضع الكريم تحت ضمادة معقمة لمدة 2 إلى 5 ساعات.</p><p dir="RTL"><strong>استخدمه على الجلد قبل إزالة البقع الشبيهة بالثآليل والتي تسمى &quot;الرخويات&quot;</strong></p><p dir="RTL">&bull; يمكن استخدام كريم إيملا للأطفال والمراهقين المصابين بحالة جلدية تسمى &quot;التهاب الجلد التأتبي&quot;.</p><p dir="RTL">&bull; تعتمد الجرعة المعتادة على عمر الطفل وتستخدم لمدة 30 إلى 60 دقيقة (30 دقيقة إذا كان المريض مصابًا بالتهاب الجلد التأتبي). سيخبرك طبيبك أو الصيدلي بمقدار الكريم الذي يجب استخدامه.</p><p dir="RTL">&nbsp;<strong>يستخدم على الجلد التناسلي قبل حقن التخدير الموضعي</strong></p><p dir="RTL">&bull; لا يمكن استخدام كريم إيملا بهذه الطريقة إلا من قبل المتخصصين في الرعاية الصحية للبالغين والمراهقين فوق سن 12 عامًا.</p><p dir="RTL">&bull; الجرعة المعتادة هي 1 جرام من الكريم (1 جرام إلى 2 جرام لبشرة الأعضاء التناسلية الأنثوية) لكل منطقة من الجلد بحجم 10 سم 2 (10 سم مربع).</p><p dir="RTL">&bull; يوضع الكريم تحت ضمادة معقمة. يتم ذلك لمدة 15 دقيقة على جلد الأعضاء التناسلية الذكرية ولمدة 60 دقيقة على جلد الأعضاء التناسلية الأنثوية.</p><p dir="RTL"><strong>استخدامه على الأعضاء التناسلية قبل جراحة الجلد البسيطة (مثل إزالة الثآليل)</strong></p><p dir="RTL">&bull; لا يمكن استخدام كريم إيملا بهذه الطريقة إلا من قبل المتخصصين في الرعاية الصحية للبالغين والمراهقين فوق سن 12 عامًا.</p><p dir="RTL">&bull; الجرعة المعتادة هي 5 جرام إلى 10 جرام من الكريم لمدة 10 دقائق. لا يتم استخدام ضمادة. يجب أن يبدأ الإجراء الطبي على الفور.</p><p dir="RTL"><strong>استخدامه على تقرحات الساق قبل تنظيف أو إزالة الجلد التالف</strong></p><p dir="RTL">&bull; يمكن استخدام كريم إيملا بهذه الطريقة عند البالغين ، ولكن فقط تحت إشراف طبيب أو ممرض.</p><p dir="RTL">&bull; الجرعة المعتادة هي 1 جرام إلى 2 جرام من الكريم لكل منطقة من الجلد تبلغ مساحتها 10 سم 2 حتى إجمالي 10 جرام.</p><p dir="RTL">&bull; يوضع الكريم تحت ضمادة محكمة الغلق مثل غلاف بلاستيكي. يتم ذلك لمدة 30 إلى 60 دقيقة قبل تطهير القرحة. قم بإزالة الكريم بشاش القطن وابدأ في التنظيف دون تأخير.</p><p dir="RTL">&bull; يمكن استخدام كريم إيملا قبل تنظيف تقرحات الساق حتى 15 مرة على مدى شهر إلى شهرين.</p><p dir="RTL">&bull; أنبوب كريم إيملا مخصص للاستخدام الفردي عند استخدامه على تقرحات الساق: يجب التخلص من <strong>الأنبوب الذي يحتوي على أي محتويات متبقية بعد كل مرة يتم فيها علاج المريض.</strong></p><p dir="RTL"><strong>اذا كنت تستخدم كريم إيملا أكثر مما يجب</strong></p><p dir="RTL">إذا كنت تستخدم كريم إيملا أكثر مما هو موصوف في هذه النشرة أو أكثر مما أخبرك به طبيبك أو الصيدلي، فتحدث إلى أحدهم على الفور ، حتى لو لم تشعر بأي أعراض.</p><p dir="RTL">يتم سرد أعراض استخدام الكثير من كريم إيملا أدناه. من غير المحتمل أن تحدث هذه الأعراض إذا تم استخدام كريم إيملا على النحو الموصى به</p><table cellspacing="0" cellpadding="0" align="right"><tbody><tr><td style="vertical-align:top"><p dir="RTL">- الشعور بالدوخة أو الدوار.</p><p dir="RTL">- وخز في الجلد حول الفم وخدر في اللسان.</p><p dir="RTL">- طعم غير طبيعي.</p><p dir="RTL">- تشوش الرؤية.</p><p dir="RTL">- طنين في الأذنين.</p><p dir="RTL">- هناك أيضًا خطر حدوث &quot;ميثيموغلوبين الدم الحاد&quot; (مشكلة في مستويات صبغة الدم). تزداد احتمالية حدوث ذلك عند تناول بعض الأدوية في نفس الوقت. إذا حدث هذا ، يصبح الجلد رمادي مزرق بسبب نقص الأكسجين.</p><p dir="RTL">في الحالات الخطيرة للجرعة الزائدة ، قد تشمل الأعراض نوبات ، وانخفاض ضغط الدم ، وبطء التنفس ، وتوقف التنفس وضربات القلب المتغيرة. قد تكون هذه الآثار مهددة للحياة.</p><p dir="RTL">إذا كانت لديك أسئلة إضافية حول استعمال الدواء, استشر الطبيب أو الصيدليّ.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="right"><tbody><tr><td style="vertical-align:top"><p dir="RTL">كأي دواء, قد يسبب استعمال إيملا 5% أعراض جانبية لدى جزء من المستخدمين.</p><p dir="RTL">توجه الى الطبيب أو الصيدليّ الخاص بك إذا أزعجك أيّ عرض جانبيّ من بين الأعراض الجانبية في التالي أو لا يبدو أنه على وشك أن ينقضي. أخبر الطبيب عن أيّ شيء أخر يسبب لك الشعور بتوعك في الوقت الذي تستعمل به إيملا 5%</p><p dir="RTL">إذا واجهت أيًا من الآثار التالية أثناء استخدام كريم إيملا، فتوقف عن استخدامه واستشر طبيبك أو الصيدلي في أقرب وقت ممكن:</p><p dir="RTL">&bull; ردود الفعل التحسسية ، التي قد تتطور في حالات نادرة إلى صدمة تأقية (طفح جلدي ، تورم ، حمى ، صعوبات في التنفس وإغماء) أثناء علاج الجلد أو الغشاء المخاطي في الأعضاء التناسلية أو قرح الساق.</p></td></tr></tbody></table><p dir="RTL">&bull; ميتهيموغلوبينية الدم (اضطراب الدم) ، والذي قد يحدث في حالات نادرة أثناء علاج الجلد ، وقد يسبب علامات وأعراض نقص تأكسد الدم (مستوى منخفض بشكل غير طبيعي من الأكسجين في الدم). يتم ملاحظة وجود ميثيموغلوبين الدم بشكل متكرر ، غالبًا فيما يتعلق بجرعة زائدة ، عند الأطفال حديثي الولادة والرضع الذين تتراوح أعمارهم بين 0 و 12 شهرًا.</p><p dir="RTL">قد يحدث في منطقة استعمال كريم إيملا 5% رد فعل خفيف (شحوب أو احمرار الجلد, تورم خفيف, شعور بلسعة أولية أو تهيّج) هذه هي ردود فعل سليمة للكريم وللمواد المخدّرة وهي تختفي في غضون وقت قصير بدون الحاجة لاستعمال وسائل إضافية.</p><p dir="RTL">إذا كنت تختبر تأثيرات مزعجة أو شاذة عندما تستعمل كريم إيملا 5%، توقف عن استعمال الكريم تحقّق مع طبيبك أو الصيدليّ في أقرب وقت ممكن.</p><p dir="RTL">أعراض جانبية شائعة (تظهر لدى 1-10 مستخدمين من بين 100):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل جلدية موضعية عابرة (شحوب, احمرار, تورم) في مكان التطبيق في أثناء العلاج بالجلد, في مخاطيات الأعضاء التناسلية أو في قروح في الساقين.</p><p dir="RTL">شعور بسفعة خفيفة أولية, تهيّج أو دفء في المنطقة المعالجة في أثناء العلاج في مخاطية الأعضاء التناسلية أو في قروح في الساقين.</p><p dir="RTL">أعراض جانبية غير شائعة (تظهر لدى 1-10 مستخدمين من بين 1,000):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بسفعة خفيفة أولية, تهيّج أو دفء في المنطقة المعالجة في أثناء العلاج في الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الشعور (وخز) في المنطقة المعالجة في أثناء العلاج بمخاطية الأعضاء التناسلية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيّج الجلد المعالج في أثناء العلاج بقروح الساقين.</p><p dir="RTL">أعراض جانبية نادرة (تظهر لدى 1-10 مستخدمين من بين 10,000):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف على شكل نقاط صغيرة في منطقة العلاج (خاصة لدى أطفال مع أكزيما بعد أوقات إبقاء مطولة أكثر للكريم( خلال العلاج في الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيّج في العينين إذا لامسها كريم إيملا 5% عن طريق الخطأ خلال العلاج بالجلد.</p><p dir="RTL">التبليغ عن الاعراض الجانبية:</p><p dir="RTL"><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ والسلامة الدوائية</p><p dir="RTL">الهاتف الموحد: 19999</p><p dir="RTL">البريد الالكتروني: &nbsp;npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: &nbsp;www.sfda.gov.sa</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دول الخليج الأخرى:</strong></p><p dir="RTL"><strong>الرجاء الإتصال بالمؤسسات والهيئات الوطنية لكل دولة.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب تخزين كريم إيملا في درجة حرارة أقل من 30&deg; ويجب عدم تجميده.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كريم إيملا هو مستحلب زيت/ماء تتكون فيه المرحلة الزيتية من خليط سهل الانصهار من ليدوكايين و بريلوكايين بنسبة 1:1</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إضافة إلى المواد الفعالة يحتوي الدواء أيضًا على:</p><p dir="RTL">ماكروغولغليسيرول هيدروكسي ستيرات ، كاربومير 974P ، هيدروكسيد الصوديوم ، ماء نقي.</p><p dir="RTL">كريم إيملا % 5 هو كريم أبيض معبأ بأنبوبة ألومنيوم من 25 جرام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة أجا للصناعات الدوائية المحدودة</p><p dir="RTL">مدينة حائل الصناعية (مدن) &ndash; شارع رقم 32</p><p dir="RTL">رقم المبنى ٦۹۷۹، حائل ٥٥٤۱٤</p><p dir="RTL">هاتف: 00966112687900</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة الطبية آخر مرة في: ديسمبر 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Imla Cream 5%
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lidocaine 2.5% w/w (25 mg/g)
Prilocaine 2.5% w/w (25 mg/g) 
For excipients, see 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White soft cream.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull;&nbsp; Topical anaesthesia of the skin in connection with:</p><p>o needle insertion, e.g. intravenous catheters or blood sampling;</p><p>o superficial surgical procedures;</p><p>in adults and in the paediatric population.</p><p>&bull;&nbsp;&nbsp; Topical anaesthesia of the genital mucosa, e.g. prior to superficial surgical procedures or infiltration anaesthesia; in adults and adolescents &ge; 12 years</p><p>&bull;&nbsp; Topical anaesthesia of leg ulcers to facilitate mechanical cleansing/debridement in adults only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administration of Imla Cream on genital mucosa, genital skin or leg ulcers should only be performed by or under the supervision of a healthcare professional.</p><p><u>Posology</u></p><p><em>Adults and adolescents</em></p><p>The details of the Indications or Procedures for use, with Dosage and Application Time are provided in Tables 1 and 2.</p><p>For further guidance on the appropriate use of the product in such procedures, please refer to <em>Method of administration.</em></p><p>Table 1 Adults and adolescents 12 years of age and above</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication/Procedure</strong></p></td><td style="vertical-align:top"><p><strong>Dosage and Application Time</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Minor procedures, e.g. needle insertion and surgical treatment of localised lesions.</p></td><td style="vertical-align:top"><p>2 g (approx half a 5 g tube) or approx. 1.5 g/10 cm2 for 1 to 5 hours1).</p></td></tr><tr><td style="vertical-align:top"><p>Dermal procedures on newly shaven skin of large body areas, e.g. laser hair removal (self-application by patient)</p></td><td style="vertical-align:top"><p>Maximum recommended dose: 60 g. Maximum recommended treated area; 600 cm2 for a minimum of 1 hour, maximum 5 hours1).</p></td></tr><tr><td style="vertical-align:top"><p>Dermal surgical procedures on larger areas in a hospital setting, e.g. split-skin grafting.</p></td><td style="vertical-align:top"><p>Approx 1.5-2 g/10 cm2 for 2 to 5 hours1).</p></td></tr><tr><td style="vertical-align:top"><p>Skin of male genital organs</p><p>Prior to injection of local anaesthetics Skin of female genital organs</p><p>Prior to injection of local anaesthetics2)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>1 g/10 cm2 for 15 minutes</p><p><strong>&nbsp;</strong></p><p>1-2 g/10 cm2 for 60 minutes</p></td></tr><tr><td style="vertical-align:top"><p><strong>Genital mucosa</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Surgical treatment of localised lesions, e.g. removal of genital warts (condylomata acuminata) and prior to injection of local anaesthetics</p></td><td style="vertical-align:top"><p>Approx 5-10 g of cream for 5-10 minutes1) 3) 4).</p></td></tr><tr><td style="vertical-align:top"><p>Prior to cervical curettage</p></td><td style="vertical-align:top"><p>10 g of cream should be administered in the lateral vaginal fornices for 10 minutes.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Leg ulcer(s)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Adults only</u></p><p>Mechanical cleansing/debridement</p></td><td style="vertical-align:top"><p>Approx 1-2 g/10 cm2 up to a total of 10 g to the leg ulcer(s) 3) 5).</p><p>Application time: 30-60 minutes.</p></td></tr></tbody></table><p>1 After a longer application time anaesthesia decreases.</p><p>2 On female genital skin, Imla Cream alone applied for 60 or 90 minutes does not provide sufficient anaesthesia for thermocautery or diathermy of genital warts.</p><p>3 Plasma concentrations have not been determined in patients treated with doses of &gt;10 g (see also section 5.2).</p><p>4 In adolescents weighing less than 20 kg the maximum dose of Imla Cream on genital mucosa should be proportionally reduced.</p><p>5 Imla Cream has been used for the treatment of leg ulcers up to 15 times over a period of 1 to 2 months without loss of efficacy or increased number or severity of adverse events.</p><p><em>Paediatric population</em></p><p>Table 2 Paediatric patients 0-11 years of age</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Age group</strong></p></td><td style="vertical-align:top"><p><strong>Procedure</strong></p></td><td style="vertical-align:top"><p><strong>Dosage and Application time</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Minor procedures, e.g. needle insertion and surgical treatment of localised lesions.</p></td><td style="vertical-align:top"><p>Approx 1g/10 cm2 for one hour (see details below)</p></td></tr><tr><td style="vertical-align:top"><p>Newborn infants and infants 0-2 months1)2)3)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Up to 1 g and 10 cm2 for one hour4)</p></td></tr><tr><td style="vertical-align:top"><p>Infants 3-11 months1) 2)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Up to 2 g and 20 cm2 for one hour5)</p></td></tr><tr><td style="vertical-align:top"><p>Toddlers and children 1-5 years</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Up to 10 g and 100 cm2 for 1-5 hours6)</p></td></tr><tr><td style="vertical-align:top"><p>Children 6-11 years</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Up to 20 g and 200 cm2 for 1-5 hours6)</p></td></tr><tr><td style="vertical-align:top"><p>Paediatric&nbsp;&nbsp;&nbsp;&nbsp; patients&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atopic dermatitis</p></td><td style="vertical-align:top"><p>Prior to removal of mollusca</p></td><td style="vertical-align:top"><p>Application time: 30 minutes</p></td></tr></tbody></table><p>1 In term newborn infants and infants below 3 months, only one single dose should be applied in any 24 hour period. For children aged 3 months and above, a maximum of 2 doses, separated by at least 12 hours can be given within any 24 hour period, see sections 4.4 and 4.8.</p><p>2 Imla Cream should not be used in infants up to 12 months of age receiving treatment with methaemoglobin- inducing agents, because of safety concerns, see sections 4.4 and 4.8.</p><p>3 Imla Cream should not be used at less than 37 weeks gestational age, because of safety concerns, see section 4.4.</p><p>4 Application for &gt; 1 hour has not been documented.</p><p>5 No clinically significant increase in methaemoglobin levels has been observed after an application time of up to 4 hours on 16 cm2.</p><p>6 After longer application time anaesthesia decreases.</p><p>Safety and efficacy for the use of Imla Cream on genital skin and genital mucosa have not been established in children younger than 12 years.</p><p>Available paediatric data do not demonstrate adequate efficacy for circumcision.</p><p><em>Elderly</em></p><p>No dose reduction is necessary in elderly patients (see sections 5.1 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>A reduction of a single dose is not necessary in patients with impaired hepatic function (see section 5.2).</p><p><em>Renal impairment</em></p><p>A dose reduction is not necessary among patients with restricted renal function. <u>Method of administration</u></p><p>Cutaneous use</p><p>The protective membrane of the tube is perforated by applying the cap.</p><p>One gram of Imla cream pressed out of a tube of 30 g is approximately 3.5 cm. If high levels of accuracy in dosing are required to prevent overdose (i.e., at doses approaching the maximum in newborn infants or if two applications may be required in a 24 hour period), a syringe can be used where 1 ml = 1 g.</p><p>A thick layer of Imla Cream should be applied to the skin, including genital skin, under an occlusive dressing. For application to larger areas, such as split-skin grafting, an elastic bandage should be applied on top of the occlusive dressing to give an even distribution of cream and protect the area. In the presence of atopic dermatitis, the application time should be reduced.</p><p>For procedures related to genital mucosa, no occlusive dressing is required. The procedure should be commenced immediately after removal of the cream.</p><p>For procedures related to leg ulcers, a thick layer of Imla Cream should be applied under an occlusive dressing. Cleansing should start without delay after removal of the cream.</p><p>The Imla Cream tube is intended for single use when used on leg ulcers: The tube with any remaining contents should be discarded after each occasion that a patient has been treated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to lidocaine and/or prilocaine or local anaesthetics of the amide type or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients with defective glucose-6-phosphate dehydrogenase, hereditary or idiopathic methaemoglobinaemia are more susceptible to active-substance-induced signs of methaemoglobinaemia. In glucose-6-phosphate dehydrogenase deficient patients the antidote methylene blue is ineffective at methaemoglobin reduction, and is capable of oxidising haemoglobin itself, and therefore methylene blue therapy cannot be given.</p><p>Due to insufficient data on absorption, Imla Cream should not be applied to open wounds (excluding leg ulcers).</p><p>Due to the potentially enhanced absorption on newly shaven skin, it is important to adhere to the recommended dosage, area and time of application (see section 4.2).</p><p>Care should be taken when applying Imla Cream to patients with atopic dermatitis. A shorter application time, 15-30 minutes, may be sufficient (see section 5.1). Application times of longer than 30 minutes in patients with atopic dermatitis may result in an increased incidence of local vascular reactions, particularly application site redness and in some cases petechia and purpura (see section 4.8). Prior to removal of mollusca in children with atopic dermatitis it is recommended to apply cream for 30 minutes.</p><p>When applied in the vicinity of the eyes, Imla cream should be used with particular care since it may cause eye irritation. Also the loss of protective reflexes may allow corneal irritation and potential abrasion. If eye contact occurs, the eye should immediately be rinsed with water or sodium chloride solution and protected until sensation returns.</p><p>Imla Cream should not be applied to an impaired tympanic membrane. Tests on laboratory animals have shown that Imla cream has an ototoxic effect when instilled into the middle ear. Animals with an intact tympanic membrane, however, show no abnormality when exposed to Imla cream in the external auditory canal.</p><p>Patients treated with anti-arrhythmics of class III (e.g., amiodarone) should be carefully monitored and ECG monitoring considered, as cardiac effects may be additive.</p><p>Lidocaine and prilocaine have bacteriocidal and antiviral properties in concentrations above 0.5 &ndash; 2%. For this reason, although one clinical study suggests that the immunisation response, as assessed by local wheal</p><p>&nbsp;</p><p>formation, is not affected when Imla Cream is used prior to BCG vaccination, the results of intracutaneous injections of live vaccines should be monitored.</p><p>Imla Cream contains macrogolglycerol hydroxystearate, which may cause skin reactions.</p><p><em>Paediatric population</em></p><p>Studies have been unable to demonstrate the efficacy of Imla Cream for heel lancing in newborn infants.</p><p>In newborn infants/infants younger than 3 months a transient, clinically insignificant increase in methaemoglobin levels is commonly observed up to 12 hours after an application of Imla Cream within the recommended dosing.</p><p>If the recommended dose is exceeded the patient should be monitored for system adverse reactions secondary to methaemoglobinaemia (see sections 4.2, 4.8 and 4.9).</p><p>Imla Cream should not be used</p><p>&bull;&nbsp; in newborn infants/infants up to 12 months of age receiving concomitant treatment with methaemoglobin- inducing agents.</p><p>&bull;&nbsp;&nbsp; in preterm newborn infants with a gestational age less than 37 weeks as they are at risk of developing increased methaemoglobin levels.</p><p>Safety and efficacy for the use of Imla Cream on genital skin and genital mucosa have not been established in children younger than 12 years.</p><p>Available paediatric data do not demonstrate adequate efficacy for circumcision.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prilocaine in high doses may cause an increase in methaemoglobin levels particularly in conjunction with methaemoglobin-inducing medicinal products (e.g. sulphonamides, nitrofurantoin, phenytoin, phenobarbital). This list is not exhaustive.</p><p>With large doses of Imla Cream, consideration should be given to the risk of additional systemic toxicity in patients receiving other local anaesthetics or medicinal products structurally related to local anaesthetics, since the toxic effects are additive.</p><p>Specific interaction studies with lidocaine/prilocaine and anti-arrhythmics class III (e.g. amiodarone) have not been performed, but caution is advised (see also section 4.4).</p><p>Medicinal products that reduce the clearance of lidocaine (e.g., cimetidine or betablockers) may cause potentially toxic plasma concentrations when lidocaine is given in repeated high doses over a long time period.</p><p><em>Paediatric population</em></p><p>Specific interaction studies in children have not been performed. Interactions are likely to be similar to the adult population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Although topical application is associated with only a low level of systemic absorption, the use of Imla Cream in pregnant women should be undertaken with care because insufficient data are available concerning the use of Imla Cream in pregnant women. However, animal studies do not indicate any direct or indirect negative effects on pregnancy, embryo-foetal development, parturition or postnatal development. Reproduction toxicity has been shown with subcutaneous/intramuscular administration of high doses of lidocaine or prilocaine much exceeding the exposure from topical application (see section 5.3).</p><p>Lidocaine and prilocaine cross the placental barrier and may be absorbed by the foetal tissues. It is reasonable to assume that lidocaine and prilocaine have been used in a large number of pregnant women and women of childbearing age. No specific disturbances to the reproductive process have so far been reported, e.g. an increased incidence of malformations or other directly or indirectly harmful effects on the foetus.</p><p><u>Breast-feeding</u></p><p>Lidocaine and, in all probability, prilocaine are excreted into breast milk, but in such small quantities that there is generally no risk of the child being affected at therapeutic dose levels. Imla Cream can be used during breast-feeding if clinically needed.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Animal studies have shown no impairment of the fertility of male or female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Imla Cream has no or negligible influence on the ability to drive and use machines when used at the recommended doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Summary of the safety profile</em></p><p>The most frequently observed adverse drug reactions (ADRs) are related to administration site conditions (transient local reactions at the application site), reported as common.</p><p><em>Tabulated list of adverse reactions</em></p><p>The incidences of the Adverse Drug Reactions (ADRs) associated with Imla Cream therapy is tabulated below. The table is based on adverse events reported during clinical trials, and/or post-marketing use. Their frequency of Adverse Reactions is listed by MedDRA System Organ Class (SOC) and at the preferred term level.</p><p>Within each System Organ Class, adverse reactions are listed under frequency categories of: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>Table 3 Adverse reactions</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Methaemoglobinaemia1</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity1, 2, 3</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Corneal irritation1</p></td></tr><tr><td style="vertical-align:top"><p>Skin&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Purpura1,</p><p>Petechiae1 (especially after longer application times in children with atopic dermatitis or mollusca contagiosa)</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; site conditions</p></td><td style="vertical-align:top"><p>Burning sensation2, 3</p><p>Application site pruritus 2, 3</p><p>Application site erythema1, 2, 3</p><p>Application site oedema 1, 2, 3</p><p>Application site warmth 2, 3</p><p>Application site pallor 1, 2, 3</p></td><td style="vertical-align:top"><p>Burning sensation1 Application site irritation3 Application site pruritus1 Application&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; site</p><p>paraesthesia2 such&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as tingling</p><p>Application site warmth1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>1 Skin</p><p>2 Genital mucosa</p><p>3 Leg ulcer</p><p><em>Paediatric population</em></p><p>Frequency, type and severity of adverse reactions are similar in the paediatric and adult age groups, except for methaemoglobinaemia, which is more frequently observed, often in connection with overdose (see section 4.9), in newborn infants and infants aged 0 to 12 months.</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>o Phone number: 19999</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><br />Saudi Arabia:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC Slates:</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rare cases of clinically significant methaemoglobinaemia have been reported. Prilocaine in high doses may cause an increase in methaemoglobin levels particularly in susceptible individuals (section 4.4), with too frequent dosing in newborn infants and infants below 12 months of age (section 4.2) and in conjunction with methaemoglobin-inducing medicinal products (e.g. sulphonamides, nitrofurantoin, phenytoin and phenobarbital). Consideration should be given to the fact that pulse oximeter values may overestimate the actual oxygen saturation in case of increased methaemoglobin fraction; therefore, in cases of suspected methaemoglobinaemia, it may be more helpful to monitor oxygen saturation by co-oximetry.</p><p>Clinically significant methaemoglobinaemia should be treated with a slow intravenous injection of methylene blue (see also section 4.4).</p><p>Should other symptoms of systemic toxicity occur, the signs are anticipated to be similar in nature to those following the administration of local anaesthetics by other routes of administration. Local anaesthetic toxicity is manifested by symptoms of nervous system excitation and, in severe cases, central nervous and cardiovascular depression. Severe neurological symptoms (convulsions, CNS depression) must be treated symptomatically by respiratory support and the administration of anticonvulsive medicinal products; circulatory signs are treated in line with recommendations for resuscitation.</p><p>Since the rate of absorption from intact skin is slow, a patient showing signs of toxicity should be kept under observation for several hours following emergency treatment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: anaesthetics, local; amides ATC code: N01B B20</p><p><u>Mechanism of action</u></p><p>Imla Cream provides dermal anaesthesia through the release of lidocaine and prilocaine from the cream into the epidermal and dermal layers of the skin and the vicinity of dermal pain receptors and nerve endings.</p><p>Lidocaine and prilocaine are amide-type local anaesthetics. They both stabilise neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby producing local anaesthesia. The quality of anaesthesia depends upon the application time and the dose.</p><p><u>Skin</u></p><p>Imla Cream is applied to intact skin under an occlusive dressing. The time needed to achieve reliable anaesthesia of intact skin is 1 to 2 hours, depending on the type of procedure. The local anaesthetic effect improves with longer application times from 1 to 2 hours in most parts of the body, with the exception of the skin of the face and the male genitals. Because of thin facial skin and high tissue blood flow, maximal local anaesthetic effect is obtained after 30-60 minutes on the forehead and on the cheeks. Similarly, local anaesthesia of the male genitals is achieved after 15 minutes. The duration of anaesthesia following the application of Imla Cream for 1 to 2 hours is at least 2 hours after removal of the dressing, except in the face where the duration is shorter. Imla Cream is equally effective and has the same anaesthetic onset time across the range of light to dark pigmented skin (skin types I to VI).</p><p>In clinical studies of Imla Cream on intact skin, no differences in safety or efficacy (including anaesthetic onset time) were observed between geriatric patients (aged 65 to 96 years) and younger patients.</p><p>Imla Cream produces a biphasic vascular response involving initial vasoconstriction followed by vasodilatation at the application site (see section 4.8). Irrespective of the vascular response, Imla Cream</p><p>&nbsp;</p><p>facilitates the needle procedure compared to placebo cream. In patients with atopic dermatitis, a similar but shorter vascular reaction is seen, with erythema occurring after 30-60 minutes, indicating more rapid absorption through the skin (see section 4.4). Imla Cream may cause a transient increase in skin thickness, partly caused by hydration of the skin under the occlusive dressing. The skin thickness decreases over the course of 15 minutes air exposure.</p><p>The depth of cutaneous anaesthesia increases with application time. In 90% of patients the anaesthesia is sufficient for the insertion of a biopsy punch (4 mm diameter) to a depth of 2 mm after 60 minutes and 3 mm after 120 minutes Imla Cream treatment.</p><p>The use of Imla Cream prior to measles-mumps-rubella or intramuscular diphtheria-pertussis-tetanus- inactivated poliovirus-Haemophilus influenzae b or Hepatitis B vaccines does not affect mean antibody titres, rate of seroconversion, or the proportion of patients achieving protective or positive antibody titres post immunisation, as compared to placebo treated patients.</p><p><u>Genital mucosa</u></p><p>Absorption from the genital mucosa is more rapid and onset time is shorter than after application to the skin.</p><p>After a 5-10 minute application of Imla Cream to female genital mucosa the average duration of effective analgesia to an argon laser stimulus, which produced a sharp, pricking pain was 15-20 minutes (individual variations in the range 5-45 minutes).</p><p><u>Leg ulcers</u></p><p>Reliable anaesthesia for the cleansing of leg ulcers is achieved after an application time of 30 minutes in most patients. An application time of 60 minutes may improve the anaesthesia further. The cleansing procedure should start within 10 minutes of removal of the cream. Clinical data from a longer waiting period are not available. Imla Cream reduces the postoperative pain for up to 4 hours after debridement. Imla Cream reduces the number of cleansing sessions required to achieve a clean ulcer compared to debridement with placebo cream. No negative effects on ulcer healing or bacterial flora have been observed.</p><p><u>Paediatric population</u></p><p>Clinical studies involved more than 2,300 paediatric patients of all age groups and demonstrated efficacy for needle pain (venipuncture, cannulation, s.c. and i.m. vaccinations, lumbar puncture), laser treatment of vascular lesions, and curettage of molluscum contagiosum. Imla Cream diminished the pain of both needle insertion and injection of vaccines. Analgesic efficacy increased from 15 to 90 minutes application on normal skin but on vascular lesions 90 minutes provided no benefit over 60 min. There was no benefit of Imla Cream versus placebo for liquid nitrogen cryotherapy of common warts. No adequate efficacy for circumcision could be demonstrated.</p><p>Eleven clinical studies in newborn infants and infants showed that peak methaemoglobin concentrations occur about 8 hours after epicutaneous Imla Cream administration, are clinically insignificant with recommended dosage, and return to normal values after about 12-13 hours. Methaemoglobin formation is related to the cumulative amount of prilocaine percutaneously absorbed, and may therefore increase with prolonged application times of Imla Cream.</p><p>The use of Imla Cream prior to measles-mumps-rubella or intramuscular diphtheria-pertussis-tetanus- inactivated poliovirus-Haemophilus influenzae b or Hepatitis B vaccines did not affect mean antibody titres, rate of seroconversion, or the proportion of patients achieving protective or positive antibody titres post immunisation, as compared to placebo treated patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption, distribution, biotransformation and elimination</u></p><p>The systemic absorption of lidocaine and prilocaine from Imla Cream is dependent upon the dose, area of application and application time. Additional factors include thickness of the skin (which varies in different areas of the body), other conditions such as skin diseases, and shaving. Following application to leg ulcers, the characteristics of the ulcers may also affect the absorption. Plasma concentrations after treatment with Imla Cream are 20-60% lower for prilocaine than for lidocaine, because of a larger volume of distribution and more rapid clearance. The major elimination pathway of lidocaine and prilocaine is via hepatic metabolism and metabolites are renally excreted. However, the rate of metabolism and elimination of the local anaesthetics after topical application of Imla Cream are governed by the rate of absorption. Therefore, a decrease in clearance, such as in patients with severely impaired liver function, has limited effects on the systemic plasma concentrations after a single dose of Imla Cream, and after single doses repeated once daily short term (up to 10 days).</p><p>&nbsp;</p><p>Symptoms of local anaesthetic toxicity become increasingly apparent at increasing plasma concentration from 5 to 10 &mu;g/ml of either active substance. It should be assumed that the toxicity of lidocaine and prilocaine are additive.</p><p><em>Intact skin</em></p><p>Following application to the thigh in adults (60 g cream/400 cm2&nbsp;&nbsp;for 3 hours), the extent of absorption was approximately 5% of lidocaine and prilocaine. Maximum plasma concentrations (mean 0.12 and 0.07 &mu;g/ml) were reached approximately 2-6 hours after application.</p><p>The extent of systemic absorption was approximately 10% following application to the face (10 g/100 cm2&nbsp;&nbsp;for 2 hours). Maximum plasma concentrations (mean 0.16 and 0.06 &mu;g/ml) were reached after approximately 1.5-3 hours.</p><p>In studies of split-skin grafting in adults application for up to 7 hours 40 minutes to the thigh or upper arm to an area of up to 1,500 cm2&nbsp;&nbsp;resulted in maximum plasma concentrations not exceeding 1.1 &micro;g/ml lidocaine and 0.2 &micro;g/ml prilocaine.</p><p><em>Genital mucosa</em></p><p>After the application of 10 g Imla Cream for 10 minutes to vaginal mucosa, maximum plasma concentrations of lidocaine and prilocaine (mean 0.18 &micro;g/ml and 0.15 &micro;g/ml respectively) were reached after 20-45 minutes.</p><p><em>Leg ulcer</em></p><p>Following a single application of 5 to 10 g of Imla Cream to leg ulcers with an area of up to 64 cm2&nbsp;&nbsp;for 30 minutes, the maximum plasma concentrations of lidocaine (range 0.05-0.25 &micro;g/ml, one individual value of</p><p>0.84 &micro;g/ml) and of prilocaine (0.02-0.08 &micro;g/ml) were reached within 1 to 2.5 hours.</p><p>After an application time of 24 hours to leg ulcers with an area of up to 50-100 cm2, the maximum plasma concentrations of lidocaine (0.19-0.71 &micro;g/ml) and of prilocaine (0.06-0.28 &micro;g/ml) were usually reached within 2 to 4 hours.</p><p>Following repeated application of 2-10 g Imla Cream to leg ulcers with an area of up to 62 cm2&nbsp;&nbsp;for 30-60 minutes 3-7 times a week for up to 15 doses during a period of one month, there was no apparent accumulation in plasma of lidocaine and its metabolites monoglycinexylidide and 2,6-xylidine or of prilocaine and its metabolite ortho-toluidine. The maximum observed plasma concentration for lidocaine, monoglycinexylidide and 2,6-xylidine were 0.41, 0.03 and 0.01 &micro;g/ml respectively. The maximum observed plasma concentrations for prilocaine and ortho-toluidine were 0.08 &micro;g/ml and 0.01 &micro;g/ml respectively.</p><p>Following repeated application of 10 g Imla Cream to chronic leg ulcers with an area between 62-160 cm2&nbsp;&nbsp;for 60 minutes once daily during 10 consecutive days, the mean maximum plasma concentration of the sum of lidocaine and prilocaine concentrations was 0.6 &micro;g/ml. The maximum concentration does not depend on the patient&acute;s age but is significantly (p&lt;0.01) related to the size of the ulcer area. Increasing the ulcer area by 1 cm2&nbsp;&nbsp;results&nbsp;in&nbsp;an&nbsp;increased&nbsp;Cmax&nbsp; for&nbsp;the&nbsp;sum&nbsp;of&nbsp;lidocaine and prilocaine concentrations of 7.2 ng/ml. The sum of the maximum plasma concentrations of lidocaine and prilocaine is less than one-third of those associated with toxic reactions, with no apparent accumulation over 10 days.</p><p><em>Special populations Elderly patients</em></p><p>Plasma concentrations of lidocaine and prilocaine in both geriatric and non-geriatric patients following application of Imla Cream to intact skin are very low and well below potentially toxic levels.</p><p><em>Paediatric population</em></p><p>The maximum plasma concentrations of lidocaine and prilocaine after application of Imla Cream in paediatric patients of different ages were also below potentially toxic levels. See table 4.</p><p><strong>Table 4 Plasma concentrations of lidocaine and prilocaine in paediatric age groups from 0 months to 8 years of age</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Age</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Applied amount of cream</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Application&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; time&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the cream on the skin</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Plasma </strong><strong>concentration [ng/ml]</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Lidocaine</strong></p></td><td style="vertical-align:top"><p><strong>Prilocaine</strong></p></td></tr><tr><td style="vertical-align:top"><p>0 - 3 months</p></td><td style="vertical-align:top"><p>1 g/10 cm2</p></td><td style="vertical-align:top"><p>1 hour</p></td><td style="vertical-align:top"><p>135</p></td><td style="vertical-align:top"><p>107</p></td></tr><tr><td style="vertical-align:top"><p>3 - 12 months</p></td><td style="vertical-align:top"><p>2 g/16 cm2</p></td><td style="vertical-align:top"><p>4 hours</p></td><td style="vertical-align:top"><p>155</p></td><td style="vertical-align:top"><p>131</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>2 - 3 years</p></td><td style="vertical-align:top"><p>10 g/100 cm2</p></td><td style="vertical-align:top"><p>2 hours</p></td><td style="vertical-align:top"><p>315</p></td><td style="vertical-align:top"><p>215</p></td></tr><tr><td style="vertical-align:top"><p>6 - 8 years</p></td><td style="vertical-align:top"><p>10 - 16 g/100-160 cm2 (1 g/</p><p>10 cm2)</p></td><td style="vertical-align:top"><p>2 hours</p></td><td style="vertical-align:top"><p>299</p></td><td style="vertical-align:top"><p>110</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal studies the toxicity noted after high doses of either lidocaine or prilocaine, alone or in combination, consisted of effects on the central nervous and cardiovascular systems. When lidocaine and prilocaine were combined, only additive effects were seen, with no indication of synergism or unexpected toxicity. Both active substances were shown to have a low oral acute toxicity, providing a good safety margin in the event that Imla Cream is inadvertently swallowed. In studies on reproduction toxicity, embryotoxic or fetotoxic effects of lidocaine were detected at doses of 25 mg/kg s.c. in the rabbit and for prilocaine starting at doses of 100 mg/kg i.m. in the rat. At doses below the maternal toxic range in the rat, lidocaine has no effect on the postnatal development of the offspring. An impairment of the fertility of male or female rats by lidocaine or prilocaine was not observed. Lidocaine crosses the placental barrier by means of simple diffusion. The ratio of the embryofetal dose to the maternal serum concentration is 0.4 to 1.3.</p><p>Neither local anaesthetic showed a genotoxic potential in either in vitro or in vivo genotoxicity tests. Cancer studies have not been performed with either lidocaine or prilocaine alone or in combination, due to the indication and duration of therapeutic use of these active substances.</p><p>A metabolite of lidocaine, 2,6-dimethylaniline, and a metabolite of prilocaine, &sigma;-toluidine, showed evidence of genotoxic activity. These metabolites have been shown to have carcinogenicity potential in preclinical toxicological studies evaluating chronic exposure. Risk assessments comparing the calculated maximum human exposure from intermittent use of lidocaine and prilocaine, with the exposure used in preclinical studies, indicate a wide margin of safety for clinical use.</p><p>Local tolerance studies using a 1:1 (w/w) mixture of lidocaine and prilocaine as an emulsion, cream or gel indicated that these formulations are well tolerated by intact and damaged skin and mucosal membranes.</p><p>A marked irritative reaction was seen after single ocular administration of a 50 mg/g lidocaine + prilocaine 1:1 (w/w) emulsion, in an animal study. This is the same concentration of local anaesthetics and a similar formulation as for Imla Cream. This ocular reaction may have been influenced by the high pH of the formulation of the emulsion (approximately 9), but is probably also partly a result of the irritative potential of the local anaesthetics themselves.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Polyoxyl 40 Hydrogenated Castor Oil</p><p>-&nbsp; Carbopol 974P NF Polymer</p><p>-&nbsp; Sodium Hydroxide</p><p>-&nbsp; Purified Water</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Month
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C, Do not freeze</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Imla cream is an Oil/Water emulsion in which the oil phase consist of an eutectic mixture of Lidocaine and Prilocaine in the ratio 1:1.</p><p>Imla cream is available in a pack contains 25 gm aluminium tube.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Precautions to be taken before handling or administering the medicinal product</u></em></p><p>Persons frequently applying or removing cream should ensure that contact is avoided in order to prevent the development of hypersensitivity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA Pharmaceutical Industries Company, Ltd. Hail Industrial City MODON, Street No 32
PO Box 6979 , Hail 5514
Kingdom of Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>